We are testing three new medications for people aged 16 to 75 with primary focal segmental glomerulosclerosis or minimal change disease. The goal is to see if they can reduce protein in urine and improve kidney function compared to a placebo.
Health conditions and diseases that the clinical trial is designed to study and treat.
Focal Segmental Glomerulosclerosis (FSGS) is a kidney disease that affects the glomeruli, leading to scarring and potential kidney failure. It can cause symptoms like protein in the urine, swelling, and high blood pressure.
Minimal Change Disease (MCD) is a kidney disorder that causes nephrotic syndrome, primarily affecting children. It leads to symptoms such as swelling, proteinuria, and high cholesterol levels.
Immune system diseases are conditions where the immune system does not function properly, leading to various health issues. This category includes a range of disorders, some of which may be rare.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
